How Gilead Can Spend Its $32 Billion Stockpile to Reignite Investor Optimism
Sliding hepatitis C treatment sales and discouraging news regarding its clinical-stage drug pipeline caused Gilead Sciences shares to tumble 29% in 2016. Can management rekindle investor optimism in 2017?
In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss what Gilead Sciences may do to get back on track, including how management could use its $31 billion cash stockpile to spark growth.
In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss what Gilead Sciences may do to get back on track, including how management could use its $31 billion cash stockpile to spark growth.